For example, these technologies recently led to the identification of frequent mutations in anaplastic lymphoma kinase (ALK) gene in both familial and sporadic neuroblastoma cases; as a result, ALK inhibitors are currently in clinical trials with promising preliminary results [4,5,6]. This evidence concerns the gene ALK and neuroblastoma.